While rescheduling cannabis to Schedule III might alleviate some challenges, Macias warns it could open the door for Big Pharma to monopolize the industry. “Rescheduling could push out the small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback